MRD assays most commonly include primer designed to the NPM1 mutations type A, B, and D because these three mutations together represent the vast majority of AML cases (type A mutation represents 70–80% of all mutations, while types B and D together represent an additional 15–20%) [71,74,77]. Here, NPM1 is linked to acute myeloid leukemia.